Related Experiment Video
Updated: May 25, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
A Case of EGFR-mutant Squamous Cell Lung Cancer Treated With Necitumumab Combination Therapy
Minehiko Inomata1, Daisuke Furukawa2, Naoki Takata2
1First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan; minomata@med.u-toyama.ac.jp.
Background/Aim:
There is insufficient evidence regarding the optimal treatment for squamous cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations, and a standard treatment strategy has not been established.
Case Report:
A 60-year-old woman was diagnosed with advanced EGFR-mutant squamous cell lung cancer. She was treated with EGFR tyrosine kinase inhibitors and then received the combined therapy of cytotoxic agents plus immune checkpoint inhibitors as third-line therapy. She was then treated with the fourth-line combination therapy of cisplatin, gemcitabine, and necitumumab, which resulted in a progression-free survival of 5.0 months and shrinkage of the liver metastatic lesion.
Conclusion:
The combination therapy of cisplatin, gemcitabine, and necitumumab was effective in treating pretreated EGFR-mutant squamous cell lung cancer in this case. It is necessary to accumulate more evidence to determine the most effective treatment for advanced EGFR-mutant squamous cell lung cancer.
Insights
For advanced EGFR-mutant squamous cell lung cancer, a combination of cisplatin, gemcitabine, and necitumumab showed effectiveness. Further research is needed to establish optimal treatment strategies for these patients.
Area of Science:
- Oncology
- Medical Research
Background:
- Optimal treatment for EGFR-mutant squamous cell lung cancer lacks sufficient evidence.
- A standardized treatment strategy is not yet established for this patient population.
Purpose of the Study:
- To report a case of advanced EGFR-mutant squamous cell lung cancer treated with a novel combination therapy.
- To evaluate the efficacy of fourth-line cisplatin, gemcitabine, and necitumumab in a pretreated patient.
Main Methods:
- A 60-year-old female patient with advanced EGFR-mutant squamous cell lung cancer was treated sequentially.
- Third-line therapy involved cytotoxic agents plus immune checkpoint inhibitors.
- Fourth-line therapy consisted of cisplatin, gemcitabine, and necitumumab.
Main Results:
- The patient achieved a progression-free survival of 5.0 months with the fourth-line combination therapy.
- Significant shrinkage of liver metastatic lesions was observed.
Conclusions:
- Combination therapy with cisplatin, gemcitabine, and necitumumab demonstrated efficacy in a pretreated EGFR-mutant squamous cell lung cancer case.
- More evidence is required to determine the most effective treatment for advanced EGFR-mutant squamous cell lung cancer.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...